Semnur Pharmaceuticals, Inc. Underwriting Income (Loss)
Semnur Pharmaceuticals, Inc. (SMNR) reported Underwriting Income (Loss) of $866.25 thousand for the 1-month period ending 2023-11-20, per its 10-Q filed 2024-05-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:UnderwritingIncomeLoss · last filed 2024-05-22
- 2023-11-20: Underwriting Income (Loss) 1 month $866.25K.
| Period end | Underwriting Income (Loss) 1 month |
|---|---|
| 2023-11-20 | $866.25K 10-Q · filed 2024-05-22 |